Literature DB >> 26359569

Ectopic Corticotropin-Producing Neuroendocrine Tumor of the Pancreas Treated With 177Lu DOTATATE Induction and Maintenance Peptide Receptor Radionuclide Therapy.

William Makis1, Karey McCann, Terence A Riauka, Alexander J B McEwan.   

Abstract

A 57-year-old woman diagnosed with ectopic Cushing syndrome was found to have a 111In-octreotide-avid corticotropin-producing pancreatic neuroendocrine tumor with liver metastases. She was treated with 4 induction and 4 maintenance cycles of 177Lu-DOTATATE, which normalized her serum corticotropin levels and dramatically reduced the size of the pancreatic primary and liver metastases.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26359569     DOI: 10.1097/RLU.0000000000000971

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN: 0363-9762            Impact factor:   7.794


  4 in total

Review 1.  Treatment of symptomatic neuroendocrine tumor syndromes: recent advances and controversies.

Authors:  Tetsuhide Ito; Lingaku Lee; Robert T Jensen
Journal:  Expert Opin Pharmacother       Date:  2016-09-23       Impact factor: 3.889

Review 2.  Management of functional neuroendocrine tumors of the pancreas.

Authors:  Kjell Öberg
Journal:  Gland Surg       Date:  2018-02

3.  Position Statement on the Diagnosis, Treatment, and Response Evaluation to Systemic Therapies of Advanced Neuroendocrine Tumors, With a Special Focus on Radioligand Therapy.

Authors:  Jaume Capdevila; Enrique Grande; Rocío García-Carbonero; Marc Simó; Mª Isabel Del Olmo-García; Paula Jiménez-Fonseca; Alberto Carmona-Bayonas; Virginia Pubul
Journal:  Oncologist       Date:  2022-04-05

4.  Peptide receptor radionuclide therapy controls inappropriate calcitriol secretion in a pancreatic neuro-endocrine tumor: a case report.

Authors:  Maarten Haemels; Thierry Delaunoit; Koen Van Laere; Eric Van Cutsem; Chris Verslype; Christophe M Deroose
Journal:  BMC Gastroenterol       Date:  2020-10-02       Impact factor: 3.067

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.